- Home
- ITCI vs CHH Comparison
ITCI vs CHH Comparison
Compare ITCI & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITCI
- CHH
- Stock Information
- Founded
- ITCI 2002
- CHH 1939
- Country
- ITCI United States
- CHH United States
- Employees
- ITCI N/A
- CHH N/A
- Industry
- ITCI Biotechnology: Pharmaceutical Preparations
- CHH Hotels/Resorts
- Sector
- ITCI Health Care
- CHH Consumer Discretionary
- Exchange
- ITCI Nasdaq
- CHH Nasdaq
- Market Cap
- ITCI 8.0B
- CHH 6.8B
- IPO Year
- ITCI N/A
- CHH 1997
- Fundamental
- Price
- ITCI $85.60
- CHH $149.68
- Analyst Decision
- ITCI Strong Buy
- CHH Hold
- Analyst Count
- ITCI 12
- CHH 11
- Target Price
- ITCI $97.67
- CHH $129.00
- AVG Volume (30 Days)
- ITCI 771.8K
- CHH 381.5K
- Earning Date
- ITCI 10-30-2024
- CHH 11-04-2024
- Dividend Yield
- ITCI N/A
- CHH 0.77%
- EPS Growth
- ITCI N/A
- CHH N/A
- EPS
- ITCI N/A
- CHH 5.17
- Revenue
- ITCI $613,728,000.00
- CHH $779,010,000.00
- Revenue This Year
- ITCI $48.25
- CHH $109.47
- Revenue Next Year
- ITCI $38.47
- CHH $3.20
- P/E Ratio
- ITCI N/A
- CHH $28.93
- Revenue Growth
- ITCI 46.08
- CHH 3.06
- 52 Week Low
- ITCI $58.14
- CHH $108.91
- 52 Week High
- ITCI $93.45
- CHH $150.36
- Technical
- Relative Strength Index (RSI)
- ITCI 55.65
- CHH 73.29
- Support Level
- ITCI $81.83
- CHH $143.91
- Resistance Level
- ITCI $86.36
- CHH $147.05
- Average True Range (ATR)
- ITCI 2.54
- CHH 2.88
- MACD
- ITCI -0.76
- CHH 0.19
- Stochastic Oscillator
- ITCI 31.15
- CHH 94.06
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
About CHH Choice Hotels International Inc.
As of Dec. 31, 2023, Choice Hotels operated 633,000 rooms across 15 brands addressing the economy and midscale segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total domestic rooms), while Ascend and Cambria (7% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added around 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 79% of total rooms in 2023.